These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 14729652)

  • 1. Effector cell-derived lymphotoxin alpha and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Hylind JC; Dutton RW
    Cancer Res; 2004 Jan; 64(1):406-14. PubMed ID: 14729652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.
    Helmich BK; Dutton RW
    J Immunol; 2001 Jun; 166(11):6500-8. PubMed ID: 11359800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis.
    Hollenbaugh JA; Reome J; Dobrzanski M; Dutton RW
    J Immunol; 2004 Aug; 173(3):1738-43. PubMed ID: 15265903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions.
    Li L; Sad S; Kägi D; Mosmann TR
    J Immunol; 1997 May; 158(9):4152-61. PubMed ID: 9126975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perforin-independent CD8(+) T-cell-mediated cytotoxicity of alveolar epithelial cells is preferentially mediated by tumor necrosis factor-alpha: relative insensitivity to Fas ligand.
    Liu AN; Mohammed AZ; Rice WR; Fiedeldey DT; Liebermann JS; Whitsett JA; Braciale TJ; Enelow RI
    Am J Respir Cell Mol Biol; 1999 May; 20(5):849-58. PubMed ID: 10226053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer.
    Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA
    J Immunol; 2006 Dec; 177(11):8191-201. PubMed ID: 17114496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
    Kemp RA; Ronchese F
    J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
    Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
    J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes.
    Vukmanovic-Stejic M; Vyas B; Gorak-Stolinska P; Noble A; Kemeny DM
    Blood; 2000 Jan; 95(1):231-40. PubMed ID: 10607707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine-deficient CD8+ Tc1 cells induced by IL-4: retained inflammation and perforin and Fas cytotoxicity but compromised long term killing of tumor cells.
    Sad S; Li L; Mosmann TR
    J Immunol; 1997 Jul; 159(2):606-13. PubMed ID: 9218575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    Clin Immunol; 2001 Jan; 98(1):70-84. PubMed ID: 11141329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity and weak CD40 ligand expression of CD8+ type 2 cytotoxic T cells restricts their potential B cell helper activity.
    Sad S; Krishnan L; Bleackley RC; Kägi D; Hengartner H; Mosmann TR
    Eur J Immunol; 1997 Apr; 27(4):914-22. PubMed ID: 9130644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
    Winter H; Hu HM; Urba WJ; Fox BA
    J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
    Prévost-Blondel A; Neuenhahn M; Rawiel M; Pircher H
    Eur J Immunol; 2000 Sep; 30(9):2507-15. PubMed ID: 11009083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8+ T cell subsets TC1 and TC2 cause different histopathologic forms of murine cardiac allograft rejection.
    Delfs MW; Furukawa Y; Mitchell RN; Lichtman AH
    Transplantation; 2001 Mar; 71(5):606-10. PubMed ID: 11292288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.